Americans love their pets, but rising veterinary bills are making owners increasingly selective about when they visit the clinic.
That spending pressure has weighed on animal healthcare companies, creating concerns about slowing growth across the industry. Yet one major diagnostics provider just delivered double-digit revenue growth and raised its annual forecast.
Growth Picks (Sponsored)
Many investors are seeing solid gains in today’s market, but solid gains often hide opportunities with far greater potential.
A new analysis highlights the 5 Stocks Set to Double, selected from thousands of companies showing early signs of powerful growth.
These picks feature strong fundamentals and technical indicators that often appear before meaningful upside.
Past editions of this research uncovered gains of +175%, +498%, and +673%.
Download the 5 Stocks Set to Double. Free Today.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
What Just Happened
IDEXX Laboratories (NASDAQ: IDXX) reported third-quarter revenue of $1.21 billion, up 10% year over year and ahead of Wall Street's approximately $1.19 billion estimate. Earnings reached $4.01 per share, increasing 18% and beating expectations of roughly $3.71.
Management raised its 2026 revenue outlook to between $4.74 billion and $4.77 billion, a $32 million increase at the midpoint. Full-year EPS guidance also increased to $14.96 to $15.16, representing approximately 15% annual growth.
The results sent shares surging nearly 22% on Monday, making IDEXX one of the market's standout performers.
But the most interesting development was buried beneath the headline figures. U.S. veterinary visits declined approximately 1.8% during the quarter, yet the company's recurring diagnostic revenue continued growing at a double-digit pace.
That disconnect is central to the investment opportunity.
Fewer Vet Visits, More Diagnostic Spending
IDEXX develops diagnostic equipment, laboratory testing services, and software used by veterinary clinics worldwide. Its products help veterinarians detect diseases, monitor chronic conditions, and evaluate animal health.
The company's Companion Animal Group accounts for more than 90% of revenue, making veterinary diagnostics its primary growth engine.
During Q3, recurring diagnostic revenue increased 11% organically to approximately $967 million. U.S. growth reached 9.6%, while international markets delivered nearly 14% organic expansion.
Those numbers are impressive given the weakness in veterinary clinic traffic.
The explanation is straightforward: veterinarians are performing more diagnostic tests during the visits that do occur.
Management highlighted rising testing frequency, broader screening panels, and increasing adoption of its newer products. Aging pets are another important factor because older animals generally require more frequent monitoring.
This creates an attractive opportunity. IDEXX can expand revenue by increasing the number and value of tests performed per patient, even without an increase in clinic visits.
The Installed Base Creates Recurring Revenue
One of IDEXX's strongest competitive advantages comes from its diagnostic equipment.
The company sells laboratory analyzers that veterinary clinics use to perform blood tests and other diagnostic procedures. Once those systems are installed, clinics regularly purchase the consumables and testing materials required to operate them.
That creates recurring revenue from an expanding installed base of equipment.
During Q3, IDEXX placed more than 1,900 inVue Dx analyzers, bringing the installed base to nearly 11,000 instruments. Its broader global premium instrument installed base increased 11% year over year.
These installations helped drive 15% organic growth in VetLab consumables revenue.
The economics are attractive because every additional analyzer creates opportunities for future consumables sales. More importantly, clinics become familiar with IDEXX equipment and testing procedures, making it less convenient to switch suppliers.
IDEXX also benefits when existing customers increase utilization. A clinic performing more tests generates additional recurring revenue without requiring another equipment sale.
That combination of customer retention, installed-base growth, and higher utilization supports durable expansion.
Cancer Screening Could Be The Next Growth Catalyst
One of the company's most promising innovations is IDEXX Cancer Dx, a blood-based screening test designed to help veterinarians detect certain cancers in dogs.
Cancer is a major health concern for aging pets, but routine screening has historically been limited compared with human healthcare.
IDEXX is attempting to change that by making cancer screening more accessible during regular veterinary appointments.
Management reported that more than 14,000 customers have ordered and used Cancer Dx. Approximately 70% of test runs are performed alongside broader blood-work panels at its reference laboratories.
That creates an important commercial advantage. Cancer screening can introduce additional diagnostic revenue while encouraging clinics to perform more comprehensive testing.
The company has also expanded Cancer Dx into a multi-cancer panel, broadening its potential applications.
However, the product remains in an early commercialization phase. Investors should distinguish between the number of clinics adopting the test and the recurring revenue those clinics ultimately generate.
The long-term opportunity depends on widespread clinical acceptance, consistent utilization, and demonstrated value to veterinarians and pet owners.
Buy a stock the second it IPOs, or wait a full year?
Cash Flow Advantage (Sponsored)
Zero debt. About 64 cents kept from every dollar coming in. That's one stock in 10 Smart Money Moves.
Show me the gold royalty name.
Also inside: a defense contractor paid by government budgets, an energy giant with a growing dividend, and a household-name staple.
Give me all 10 names.
Plus 5 more, each with name, ticker, and reasoning. Zero cost.
Open the free report.
*This ad is sent on behalf of Guardian Financial Publishing LLC, doing business as Stable Financial Publishing, 1013 Centre Road Suite 403-D, Wilmington, DE 19805. Nothing here is investment, financial, legal, or tax advice, and it is not a recommendation or solicitation to buy or sell any security. Investing involves substantial risk, including loss of principal; small-cap and low-priced stocks carry particular risk, including the possible loss of your entire investment. Past performance does not guarantee future results. Stable Financial Publishing, its owners, employees and contributors may hold positions in securities mentioned and may trade them at any time. References to Elon Musk and SpaceX are for informational purposes only; Stable Financial Publishing is not affiliated with, endorsed by, or sponsored by Elon Musk or SpaceX. Privacy: https://guardian.pub/privacy-policy/ · Terms: https://guardian.pub/terms-of-service/
International Markets Are Becoming More Important
IDEXX's international business is providing another growth opportunity.
Recurring companion-animal diagnostic revenue outside the United States increased approximately 14% organically during Q3, significantly outpacing domestic growth.
Management highlighted commercial expansion across markets including France, Spain, South Korea, and Canada.
These markets offer opportunities to increase the use of in-clinic diagnostic equipment and laboratory services as veterinary practices adopt more sophisticated testing procedures.
The company's international expansion also reduces its dependence on U.S. consumer spending trends.
However, international growth introduces additional currency exposure, regulatory complexity, and differences in veterinary spending habits.
The opportunity is substantial, but investors should monitor whether international revenue growth translates into consistent profit expansion rather than requiring increasingly expensive commercial investments.
Profit Margins And Cash Flow Are Improving
IDEXX's financial performance demonstrates the advantages of its recurring revenue model.
Third-quarter gross margin increased to 62.9%, up from 61.8% a year earlier. Operating margin improved to 33.1%, representing a 100-basis-point expansion.
Higher testing volumes, favorable product mix, and operating efficiencies helped offset spending on new products and commercial expansion.
Cash generation was equally encouraging.
Operating cash flow reached approximately $450 million, while free cash flow increased to $421 million from $371 million a year earlier.
Through the first nine months of 2026, free cash flow reached approximately $978 million, increasing nearly 34%.
Management expects full-year free cash flow to represent 95% to 100% of net income.
That strong cash conversion provides flexibility to invest in innovation, pursue acquisitions, and repurchase shares without relying heavily on external financing.
The Valuation Just Became More Demanding
IDEXX's financial performance is attractive, but the stock's extraordinary earnings reaction creates an important valuation challenge.
Following Monday's rally, the company commands a market capitalization of approximately $53 billion.
That represents roughly 45 times the midpoint of management's projected 2026 earnings and more than 11 times annual revenue.
Those are substantial premiums for a business generating approximately 10% revenue growth.
The valuation reflects confidence that IDEXX can maintain double-digit diagnostic expansion, introduce successful new products, and continue improving profitability.
But strong businesses do not automatically make attractive investments at every price.
If earnings growth slows toward the high-single-digit range, investors could reassess how much they are willing to pay for future profits.
The most compelling entry opportunities would therefore come from meaningful pullbacks rather than immediately following such a dramatic rally.
Paul’s Bigger Warning (Sponsored)
Socialists now run the largest cities in America — and Dr. Ron Paul says they're STILL not the biggest threat right now.
Something worse has taken over the highest levels of Washington, while calling itself capitalism. And when it fails, he warns the crash will be blamed on capitalism itself — setting America up for a future even worse than Socialism.
See his full warning, and the #1 step to prepare, here.
*This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.
What Could Trip It Up
Weak veterinary clinic traffic remains the biggest industry risk. Pet owners facing financial pressure can postpone nonessential appointments, reducing opportunities for diagnostic testing.
Competition from other diagnostic providers could also affect pricing and customer retention.
New products introduce commercialization risks. Cancer Dx and other innovations need sustained adoption to justify continued investment.
Management also reduced its full-year operating margin outlook slightly to incorporate acquisition-related expenses, demonstrating that expansion can create near-term profitability pressure.
Finally, valuation leaves little room for disappointment. After a nearly 22% rally, even modestly weaker growth could trigger a substantial correction.
My Take
Buy on meaningful pullbacks for long-term exposure to veterinary diagnostics. IDEXX has demonstrated that its growth opportunity extends well beyond the number of animals visiting veterinary clinics. Expanding equipment installations, higher testing frequency, and new screening products create multiple sources of recurring revenue.
Its 11% diagnostic revenue growth, improving margins, and strong free cash flow support an attractive long-term investment case.
The biggest risk is paying too much for that growth. At approximately 45 times expected earnings, the stock already reflects substantial optimism. I would avoid chasing Monday's rally and look for opportunities during broader healthcare-sector weakness.
The most important indicators will be recurring diagnostic revenue growth, instrument installations, Cancer Dx adoption, and whether veterinary visits begin stabilizing.
Action Recap
🐾 Looking to buy? Wait for a meaningful pullback rather than chasing the 22% earnings rally.
📈 Already own it? Hold while recurring diagnostic revenue grows faster than overall veterinary spending.
⚠️ Main risk to respect: Weak clinic traffic and a premium valuation could pressure returns even if the underlying business continues performing well.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
